EverSource Wealth Advisors’s Sutro Biopharma STRO Stock Holding History

EverSource Wealth Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19	Closed	-$473	–	4536
2026 Q1	$473	Sell	19 -12	-39%	-$217	﹤0.01%	4077
2025 Q4	$359	Sell	31 -14	-31%	-$133	﹤0.01%	3936
2025 Q3	$394	Sell	45 -102	-69%	-$868	﹤0.01%	4008
2025 Q2	$1.05K	Buy	147 +61	+71%	+$499	﹤0.01%	3721
2025 Q1	$558	Buy	86 +80	+1,333%	+$1.26K	﹤0.01%	3419
2024 Q4	$112	Buy	+6	New	+$183	﹤0.01%	3523

Other funds holding STRO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $342M AUM

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

BWL

Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

EverSource Wealth Advisors's STRO Position: Q2 2026 in Review

EverSource Wealth Advisors sold out of Sutro Biopharma (STRO) in Q2 2026, closing a stake of 19 shares — an estimated $473 sold.

EverSource Wealth Advisors first reported a position in STRO in Q4 2024 and held it in 6 quarters. The position peaked at $1.05K in Q2 2025. 8 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

EverSource Wealth Advisors reported no remaining Sutro Biopharma position as of Q2 2026 after selling out during the quarter.
EverSource Wealth Advisors sold 19 Sutro Biopharma shares in Q2 2026, an estimated $473.
EverSource Wealth Advisors first reported a position in Sutro Biopharma in Q4 2024 and held it in 6 quarters.
EverSource Wealth Advisors's Sutro Biopharma position peaked at $1.05K in Q2 2025.
8 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.